Duration of benefit from MSC infusion in cirrhosis typically extends 6–18 months when patients adhere to standard medical management (abstinence, antivirals if applicable, diuretics). Some centres recommend booster infusions at 6–12 month intervals to sustain improvement. Durability correlates with disease stability and degree of initial graft engraftment. Unlike acute conditions, benefit may fade as underlying liver disease pathology continues; MSCs do not reverse established cirrhotic architecture but rather slow progression. Transplant-free survival at 5 years post-infusion remains incompletely documented; long-term follow-up data beyond 3 years are scarce in published literature.
Liver cirrhosis represents end-stage fibrotic liver disease, characterised by irreversible scar tissue replacing functional hepatocytes, portal hypertension, and loss of synthetic function. Stem-cell investigations focus on whether placental mesenchymal stem cells can reduce hepatic fibrosis, promote hepatocyte regeneration, and modulate the immunological and inflammatory drivers of progression. MSCs secrete hepatoprotective factors and anti-fibrotic cytokines (TGF-β antagonists, HGF, FGF) that may arrest stellate-cell activation and collagen deposition. With 89 registered trials — the largest cohort among studied conditions — and 7 currently recruiting, the biological rationale targets the fibrotic cascade rather than curative reversal of established cirrhosis. Early clinical data suggest potential for slowing decompensation, improving synthetic function markers, and delaying transplantation.
Sunt un candidat? → · Liver Cirrhosis: full overview → · Cost Ciroză Hepatică → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită